SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world’s largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.

About CMS-D008

CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.

CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:

Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical study

Presentation Number: 3079-LB

Presentation format: Poster

Date/Time: June 7, 2026 01:30 PM – 02:30 PM (Local Time)

Location: Hall D-E

Results:

50. In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.
50. In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.

The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community’s interest in the scientific value and clinical potential of CMS-D008 in

3the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.

CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

A binge-watchable library of two-minute vertical dramas — free, no app-store install, opened from a single Telegram account for the platform’s ~1 billion monthly users.

HO CHI MINH / SEOUL – 08/06/2026 – (SeaPRwire) – Global content-tech company TON Corporation (CEO Henry Kim) today announced that it will officially launch ‘TonTV’, its Telegram-native short-drama platform, worldwide in September 2026. TonTV lets the ~1 billion people who use Telegram each month instantly and freely watch short dramas with a single Telegram account — with no separate app install and no complicated sign-up.

Short drama is one of entertainment’s fastest-rising categories

Short-form drama has moved to the center of global media consumption. Global in-app revenue for short dramas reached $2.98 billion in 2025, up 115% year over year, and in Q4 2025 short-form titles overtook long-form streaming apps in downloads for the first time (733M vs. 658M), according to Sensor Tower and Omdia. With short runtimes, high completion rates, and mobile-first immersion, the format is growing fastest among younger viewers. TonTV places dramas of around two minutes at the heart of this trend — short but intense chapters that build a “can’t-stop-once-you-start” experience.

The Telegram Mini App: tearing down the barrier to entry

TonTV’s core strength is that it runs atop Telegram, a massive global platform. Existing OTT services require a long entry sequence — app-store search → download → install → sign-up → enter payment details. TonTV removes it: open the Mini App inside Telegram → watch instantly, for free.

The user reach that global OTT leaders such as Netflix and Disney+ built over years and at enormous cost is something TonTV can address from day one, across Telegram’s ~1 billion monthly users. This dramatically lowers user-acquisition cost while driving early growth through natural word-of-mouth across Telegram’s groups and channels.

Three years of preparation, and “why we can win”

TonTV did not appear overnight. Over the past three years, TON Corporation has focused on platform-technology development, global content partnerships, and a local-operations model in preparation for launch.

CTO Tony cited the following reasons TonTV can be a market “game changer” rather than a late follower:

• Frictionless reach — among the first specialized short-drama platforms to reach Telegram’s ~1 billion monthly users, free, in one click

• Free entry — anyone can start at no cost, a strong advantage for early user acquisition

• Network effects — discussion, sharing, and recommendation happen at the same moment as viewing

• Viewer-participation rewards — enjoying content itself returns benefits and rewards, building loyalty

• Simultaneous global release — worldwide at once, with no region-by-region app-store approval

On these strengths, TonTV aims to grow beyond short drama into real-time formats such as live streaming over time.

A ‘new stage’ for producers, actors, and staff worldwide

TonTV goes beyond a viewing platform to open opportunity for the global content industry. Producers can showcase work directly to a global audience; actors and staff can widen their stage across borders. For emerging teams and new actors who have struggled to get a chance at traditional broadcasters or large OTTs, TonTV offers an open stage judged on ability — creating jobs across planning, production, acting, and post-production.

“Global one platform, local content”

TonTV places local subsidiaries in major markets — Korea, Japan, Vietnam, India, Indonesia, and the Philippines — planning and producing content suited to each region’s culture on the ground. Combining a global platform’s scale with local content’s intimacy, TonTV aims to be a true global OTT where anyone can enjoy “stories from home.” The local-subsidiary model expands content and markets quickly while keeping head-office cost low.

A dual revenue model: “growth and profit together”

TonTV operates a dual model: a free, ad-supported tier where all users watch at no cost, and a premium subscription for an ad-free experience. Advertiser acquisition and content production through local subsidiaries create a cycle in which ad and subscription revenue grow with the user base. Telegram’s low acquisition cost and short-form’s high completion rates support this model.

Comment from TON Corporation CTO Tony

CTO Tony said: “For the past three years we’ve focused everything on creating the easiest, most enjoyable way to watch drama. On Telegram — a playground of a billion people — TonTV sets a new standard for short drama anyone can enjoy free, with a single account.”

He added: “TonTV will create the best experience for viewers, a new stage for creators, and new jobs for the industry — and our ambition is to become the global leader in short-drama and live content.”

Future plans

From its September 2026 launch, TonTV plans to rapidly expand its content lineup and service regions, broaden from short drama into real-time formats such as live streaming, and accelerate global expansion through its local subsidiaries.

About TON Corporation

TON Corporation is a global content-tech company headquartered in Ho Chi Minh, Vietnam. Through TonTV, its Telegram-native short-drama platform, it aims to deliver a new entertainment experience to users worldwide and open opportunity for global content creators.

Media Contact

Brand: TON Corporation

Contact: PR Team

Email: press@toncorp.io

Website: https://tontv.toncorp.io

Telegram: https://t.me/TontvOfficialChannel